BC
TAK icon

Bridgefront Capital’s Takeda Pharmaceutical TAK Stock Holding History

Bridgefront Capital’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-26,406
Closed -$489K – 742
2026
Q1 		$489K Sell
26,406
-10,173
-28% -$179K 0.12% 283
2025
Q4 		$570K Sell
36,579
-47,154
-56% -$674K 0.14% 236
2025
Q3 		$1.23M Buy
83,733
+35,250
+73% +$523K 0.36% 57
2025
Q2 		$750K Sell
48,483
-955
-2% -$14.1K 0.2% 168
2025
Q1 		$735K Buy
49,438
+8,040
+19% +$113K 0.21% 149
2024
Q4 		$548K Sell
41,398
-4,859
-11% -$66.7K 0.18% 176
2024
Q3 		$658K Buy
46,257
+24,884
+116% +$353K 0.25% 122
2024
Q2 		$277K Buy
21,373
+1,095
+5% +$14.5K 0.12% 319
2024
Q1 		$282K Sell
20,278
-522
-3% -$7.59K 0.21% 204
2023
Q4 		$297K Sell
20,800
-3,135
-13% -$44.5K 0.22% 173
2023
Q3 		$370K Buy
+23,935
New +$371K 0.26% 142
2021
Q3 		– Sell
-11,863
Closed -$200K – 645
2021
Q2 		$200K Buy
+11,863
New +$202K 0.08% 510
2021
Q1 		– Sell
-13,444
Closed -$245K – 910
2020
Q4 		$245K Buy
+13,444
New +$236K 0.08% 448

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Bridgefront Capital's TAK Position: Q2 2026 in Review

Bridgefront Capital sold out of Takeda Pharmaceutical (TAK) in Q2 2026, closing a stake of 26,406 shares — an estimated $489K sold.

Bridgefront Capital first reported a position in TAK in Q4 2020 and held it in 13 quarters. The position peaked at $1.23M in Q3 2025. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Bridgefront Capital reported no remaining Takeda Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Bridgefront Capital sold 26,406 Takeda Pharmaceutical shares in Q2 2026, an estimated $489K.
  • Bridgefront Capital first reported a position in Takeda Pharmaceutical in Q4 2020 and held it in 13 quarters.
  • Bridgefront Capital's Takeda Pharmaceutical position peaked at $1.23M in Q3 2025.
  • 376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.